Literature DB >> 3027168

Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.

A H Rook, H C Lane, T Folks, S McCoy, H Alter, A S Fauci.   

Abstract

The causative agent of the acquired immunodeficiency syndrome (AIDS) has been shown to be a human retrovirus called human T lymphotropic virus (HTLV)-III or lymphadenopathy-associated virus (LAV). The nature of the protective immune response against this virus is currently unknown. We report here results using an antibody-dependent cellular cytotoxicity (ADCC) assay which has been developed for measuring a specific immune response against HTLV-III/LAV. Forty-four sera were examined for their ability to mediate ADCC against HTLV-III/LAV-infected T cells. Sera from healthy HTLV-III/LAV seropositive individuals in the presence of mononuclear cells from healthy HTLV-III/LAV seronegative donors exhibited significantly higher levels of ADCC activity compared to sera from patients with AIDS. Western blot analysis of serum samples indicated that antibody reactivity with the p24 protein of HTLV-III/LAV correlated with higher levels of ADCC activity than did reactivity with Gp120/160. The observation that sera from healthy HTLV-III/LAV seropositive individuals mediated higher levels of ADCC activity than did sera obtained from subjects with AIDS suggests that ADCC may represent a protective immune response to infection with HTLV-III/LAV.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027168

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 2.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

3.  Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes.

Authors:  Vijaya Madhavi; Marjon Navis; Amy W Chung; Gamze Isitman; Leia H Wren; Robert De Rose; Stephen J Kent; Ivan Stratov
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

4.  Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression.

Authors:  E Ojo-Amaize; P G Nishanian; D F Heitjan; A Rezai; I Esmail; E Korns; R Detels; J Fahey; J V Giorgi
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

Review 5.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

6.  Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.

Authors:  R Ahmad; S T Sindhu; E Toma; R Morisset; J Vincelette; J Menezes; A Ahmad
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

7.  IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages.

Authors:  K Ljunggren; P A Broliden; L Morfeldt-Månson; M Jondal; B Wahren
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

8.  Biological significance of the antibody response to HIV antigens expressed on the cell surface.

Authors:  J Goudsmit; K Ljunggren; L Smit; M Jondal; E M Fenyö; M Jonda
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

9.  Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.

Authors:  M J Irwin; L S Laube; V Lee; M Austin; S Chada; C G Anderson; K Townsend; D J Jolly; J F Warner
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.